HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ts2037

a novel aminoglycoside antibiotic

Also Known As:

5,4''-diepi-arbekacin; 5,4''-diepiarbekacin; 5,4-diepi-arbekacin; 5,4-diepiarbekacin

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - ts2037: 1

Experts

1.	Akiyama, Yoshihisa: 1 article (01/2018)
2.	Fushimi, Hideki: 1 article (01/2018)
3.	Hirai, Yoko: 1 article (01/2018)
4.	Hiraiwa, Yukiko: 1 article (01/2018)
5.	Ikeda, Daishiro: 1 article (01/2018)
6.	Maebashi, Kazunori: 1 article (01/2018)
7.	Minowa, Nobuto: 1 article (01/2018)
8.	Murakami, Shoichi: 1 article (01/2018)
9.	Usui, Takayuki: 1 article (01/2018)

Related Diseases

1.	Infections 01/01/2018 - "The efficacy of TS2037 against systemic infection caused by P. " 01/01/2018 - "Therapeutic efficacies of TS2037 in the mouse models of systemic infection with MRSA were superior to those of arbekacin, vancomycin, and linezolid. "
2.	Pseudomonas Infections 01/01/2018 - "To overcome serious methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa infections, we synthesized TS2037, 5,4″-diepi-arbekacin, a novel aminoglycoside antibiotic, and evaluated its biological properties. "

Related Drugs and Biologics

1.	Vancomycin
2.	Anti-Bacterial Agents (Antibiotics)
3.	Aminoglycosides
4.	Linezolid (Zyvox)
5.	arbekacin